JOURNAL ARTICLE

Neoadjuvant Radiotherapy with Capecitabine Plus Bevacizumab for Locally Advanced Lower Rectal Cancer: Results of a Single-institute Phase II Study

Kiyoshi MaedaMasatsune ShibutaniHiroshi OtaniTatsunari FukuokaYasuhito IsekiShinji MatsutaniHisashi NagaharaToru InoueAkiko TachimoriTakafumi NishiiYoshitaka MikiMasako HosonoMasaichi Ohira

Year: 2018 Journal:   Anticancer Research Vol: 38 (7)Pages: 4193-4197   Publisher: International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts

Abstract

Although acute toxicity during CRT with bevacizumab was minimal and postoperative complications do not seem to increase, the addition of bevacizumab apparently offers no clinically-significant benefit for patients with LARC.

Keywords:
Medicine Capecitabine Bevacizumab Colorectal cancer Surgery Adverse effect Chemoradiotherapy Neoadjuvant therapy Radiation therapy Phases of clinical research Internal medicine Chemotherapy Cancer Oncology Breast cancer

Metrics

10
Cited By
0.56
FWCI (Field Weighted Citation Impact)
15
Refs
0.68
Citation Normalized Percentile
Is in top 1%
Is in top 10%

Citation History

Topics

Colorectal Cancer Surgical Treatments
Health Sciences →  Medicine →  Oncology
Colorectal Cancer Treatments and Studies
Health Sciences →  Medicine →  Oncology
Colorectal and Anal Carcinomas
Health Sciences →  Medicine →  Surgery

Related Documents

© 2026 ScienceGate Book Chapters — All rights reserved.